IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.

Nat Commun · 2025 · PMC12019336 · PMID 40268897

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

While baseline retention of CD19 intron 2 was already high in B-ALL cell lines (79.6%), IKAROS KD B-ALL cells showed a trend toward higher retention (86.1%; Supplementary Fig. 6D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.